Vanguard Portfolio Management’s Connect Biopharma Holdings CNTB Stock Holding History

Vanguard Portfolio Management’s Portfolio CNTB Stock Details CNTB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245K	Buy	+102,755	New	+$249K	﹤0.01%	3106

Other funds holding CNTB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

DMKJ

David M. Knott Jr $189M AUM 67.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Vanguard Portfolio Management's CNTB Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Connect Biopharma Holdings (CNTB) in Q2 2026: 102,755 shares worth $245K. The stake represents ﹤0.01% of the portfolio and ranks #3106 among its holdings.

34 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

Vanguard Portfolio Management held 102,755 shares of Connect Biopharma Holdings worth $245K as of Q2 2026.
Connect Biopharma Holdings was a new Vanguard Portfolio Management position in Q2 2026.
Connect Biopharma Holdings made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3106 holding.
34 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.